Research and Clinical Center for Yusho and Dioxin, Kyushu University, Fukuoka, Japan.
Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Front Immunol. 2022 May 19;13:745997. doi: 10.3389/fimmu.2022.745997. eCollection 2022.
Interleukin (IL)-37 suppresses systemic and local inflammation. It is expressed in the epidermis, the external layer of the skin, and is decreased in inflammatory skin diseases including atopic dermatitis (AD) and psoriasis. Therefore, an agent applied topically on the skin that can increase IL-37 could be promising for treating AD and psoriasis; however, the mechanism regulating IL-37 remains largely unknown. Given that IL-37 expression is induced in differentiated keratinocytes, a major component of the epidermis, and that activation of aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor, promotes keratinocyte differentiation, we hypothesized that AHR might be involved in the IL-37 expression in human keratinocytes. We analyzed normal epidermal human keratinocytes (NHEKs) treated with tapinarof and ferment filtrate (GFF), which are potent AHR modulators. We found that tapinarof and GFF upregulated IL-37 in NHEKs, which was canceled by the knockdown of AHR using siRNA transfection, indicating that AHR mediates IL-37 expression in NHEKs. Furthermore, we found that the knockdown of IL-37 resulted in the upregulation of IL-33, an alarmin cytokine with crucial roles in the pathogenesis of AD and psoriasis. These findings suggest that IL-37 negatively regulates IL-33 expression in NHEKs. Finally, we examined whether tapinarof and GFF treatment modulates IL-33 expression in NHEKs. Such treatment inhibited IL-33 expression, which was partially reversed by the knockdown of either AHR or IL-37. Taken together, our findings provide the first evidence that tapinarof and GFF could have potential to prevent IL-33-overexpressing disorders such as AD and psoriasis the AHR/IL-37 axis.
白细胞介素 (IL)-37 可抑制全身和局部炎症。它在表皮(皮肤的外层)中表达,在包括特应性皮炎 (AD) 和银屑病在内的炎症性皮肤病中减少。因此,可在皮肤上局部应用增加 IL-37 的药物有望治疗 AD 和银屑病;然而,调节 IL-37 的机制在很大程度上仍然未知。鉴于 IL-37 表达在表皮的主要成分分化的角质形成细胞中诱导,并且芳基烃受体 (AHR) 的激活,一种配体激活的转录因子,促进角质形成细胞分化,我们假设 AHR 可能参与人角质形成细胞中 IL-37 的表达。我们分析了用 tapinarof 和发酵滤液 (GFF) 处理的正常表皮人角质形成细胞 (NHEK),它们是有效的 AHR 调节剂。我们发现 tapinarof 和 GFF 在 NHEK 中上调了 IL-37,这一作用被 siRNA 转染的 AHR 敲低所取消,表明 AHR 介导了 NHEK 中 IL-37 的表达。此外,我们发现 IL-37 的敲低导致了警报细胞因子 IL-33 的上调,IL-33 在 AD 和银屑病的发病机制中起着关键作用。这些发现表明,IL-37 在 NHEK 中负调节 IL-33 的表达。最后,我们检查了 tapinarof 和 GFF 处理是否调节 NHEK 中 IL-33 的表达。这种治疗抑制了 IL-33 的表达,AHR 或 IL-37 的敲低部分逆转了这种抑制作用。总之,我们的研究结果首次提供了证据,表明 tapinarof 和 GFF 可能具有预防 AD 和银屑病等 IL-33 过表达疾病的潜力通过 AHR/IL-37 轴。